BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38618727)

  • 21. [Autologous stem cell transplantation in lymphomas and Hodgkin's disease].
    Greinix HT
    Acta Med Austriaca Suppl; 2000; 52():25-9. PubMed ID: 11261274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hematopoietic stem cell transplantation in Hodgkin's disease: questions and controversies.
    Fleury J; Legros M; Cure H; Tortochaux J; Condat P; Dionet C; Travade P; Belembaogo E; Tavernier F; Kwiatkowski F
    Leuk Lymphoma; 1994 Nov; 15(5-6):419-32. PubMed ID: 7873999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Laport GF; Williams SF
    Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
    Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
    Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 27. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
    Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
    Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
    Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
    Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
    Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma.
    Mink SA; Armitage JO
    Oncologist; 2001; 6(3):247-56. PubMed ID: 11423671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent progress in the treatment of malignant lymphoma].
    Ogura M
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
    McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
    Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma.
    Baldissera RC; Aranha JF; Oliveira GB; Vigorito AC; Eid KA; Miranda EC; De Souza CA
    Braz J Med Biol Res; 2002 Jan; 35(1):49-57. PubMed ID: 11743614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease.
    Vockerodt M; Soares M; Kanzler H; Küppers R; Kube D; Hansmann ML; Diehl V; Tesch H
    Blood; 1998 Oct; 92(8):2899-907. PubMed ID: 9763576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
    Hübel K; Fresen MM; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Jaksic O; Koristek Z; Kröger N; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Bone Marrow Transplant; 2012 Aug; 47(8):1046-50. PubMed ID: 22080971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.